Seeking Alpha

Ramsay Schrum's  Instablog

Ramsay Schrum
Send Message
VP Sales and International Operations Apparel and Garment Manufacturing Executive Education course at Harvard Business School 2010 ZLCS, TLAB, SIMG, CIM, BPAX, ASTX TRGT trading below cash right now.... nice buy opp here $4.30
View Ramsay Schrum's Instablogs on:
  • Zalicus Is Under The Radar; Potentially Developing A Game Changer

    Zalicus (ZLCS) has been trading below the radar for the past few months. I believe it is truly undervalued here at the current PPS of .65 cents and ready to explode.

    Zalicus is a discovery bio pharmaceutical company that focuses on novel pain treatments. Currently there are 126 million shares on the float trading at a PPS of .65 cents with a market cap of around 80 million. Zalicus is currently working with big pharmas like Covidien (COV), Sanofi (NYSE:SNY), and Novartis (NYSE:NVS) which is not a bad portfolio for a 80 million dollar biotech.

    There are 3 reasons why I am so bullish here at this PPS.

    1) The potential for a P3 start any moment by Sanofi on Prednisporin FOV1101 which will trigger a 3 million dollar milestone payment to Zalicus.

    2) Z944 a T-Type Calcium Channel Blocker is due for an update on Phase I results and potential Phase II start before the end of Q1

    3) The Potent Z160 an N-Type Calcium Channel Blocker has attracted huge attention from the big pharmas that are drooling to get there hands on data from the 2 PII trials. Z160 prior formulation was originally partnered in a deal with Merck for over 450 million.

    You must ask yourself at this current PPS with Fov1101 aside, leading into any data for Z160 or Z944 will the PPS rise with anticipation from the current share price of .65 cents. That question answers itself and it was shown by the previous run up going into Synavive data reaching $1.40 before negative data was released.

    Zalicus CFO Justin Rentz stated in the BIO CEO & Investor Conference on February 12th that they were looking to advance Z944 into further development after meeting with key consultants to reach the most effective path forward. That tells me that the PI data was positive and all that awaits is a conformation PR that could come at any moment.

    Of course there is the big boy drug Z160 that is currently in two Phase II trials for Lumbosacral Radiculopathy and Postherpetic Neuralgia. What does not get touched on very often is the fact that this drug will be the first pain drug that is orally administered without the side effects of an opioid. The FDA in recent years has made a huge push to regulate the amount of scrips written on the big drugs like Hydrocodone and other opioids. The growing problem in the US is becoming an epidemic with people of all ages. Z160 could set the world standard for new pain therapy and save millions of lives and families that are effected by opioid abuse.

    This possibility alone is worth more than .65 cents and I see this as a STRONG BUY here going into the coming months with nothing but upside from here on out.

    Disclosure: I am long ZLCS. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

    Tags: MDT, NVS, SNY, EPRS, long-ideas
    Feb 28 1:34 AM | Link | 1 Comment
  • Exalgo Sales Up SHARPLY From COVIDIEN 1st Q Report!!!

    This is from Covidien's COV 1st quarter results issued this morning at 6am

    Looks like the approval of Exalgo 32mg dose is going over big for Zalicus. ZLCS

    "Pharmaceuticals sales of $489 million in the first quarter were essentially unchanged from last year's first-quarter sales of $490 million. Sales of Specialty Pharmaceuticals climbed sharply from those of a year ago, primarily due to the strong performance of EXALGO®(hydromorphone HCl) ER tablets and good growth for generic products that was aided by the launch of generic CONCERTA® ER tablets."

    Should be a strong up day for ZALICUS

    GO Z!

    Disclosure: I am long ZLCS.

    Tags: EPRS, COV
    Jan 25 9:00 AM | Link | Comment!
  • Zalicus Form 4 Explained, Dont Listen To The Bashers!

    To address the Zalicus ZLCS recent Form 4 filing for the sales of roughly 100,000 shares from Dr. Mark Corrigan. This email is from the CFO Justin Renz to myself explaining the filing.

    A lot of bashers (Stocklaser) tried to use this filing last week to spin it negatively which is not the case at all. This is positive news strait from the horses mouth.

    I wish this email would have accompanied the form 4 filing to prevent the PPS downturn which should never have happened in the first place.

    "Dear Ramsay,

    I wanted to make sure that you were aware since others have asked this evening.

    As part of his hiring as our CEO in January 2010, Dr. Corrigan received 750,000 restricted stock units (RSUs) that would vest and ultimately become Zalicus common stock: (1) if Exalgo was approved and (2) he remained actively employed at Zalicus at various points over the next four years. Exalgo was approved by the FDA on March 1, 2010. Therefore each January 15, from 2011-2014, Dr. Corrigan has or may have 187,500 shares of common stock vest under these RSUs. The vesting of restricted stock causes immediate taxable income to Dr Corrigan, which has to be paid in cash. To cover this tax liability, each year Dr. Corrigan then sells the minimum number of shares necessary to cover the tax bill that comes with this share vesting and then retains the remaining shares. This year, consistent with the past two years, Dr. Corrigan only sold enough shares to cover his tax liability and remains committed to Zalicus, both for the short and long term."

    Chief Financial Officer and Treasurer


    I am bullish here at this PPS level and looking for Prednisporin P3 start, Z944 update and as well as Z160 progress report.

    Go Z

    Disclosure: I am long ZLCS.

    Jan 21 7:07 AM | Link | Comment!
Full index of posts »
Latest Followers

Latest Comments

Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.